| Автор | Eichelbaum, Michel |
| Автор | Ingelman-Sundberg, Magnus |
| Автор | Evans, William E. |
| Дата выпуска | 2006 |
| dc.description | Pharmacogenetics deals with inherited differences in the response to drugs. The best-recognized examples are genetic polymorphisms of drug-metabolizing enzymes, which affect about 30% of all drugs. Loss of function of thiopurine S-methyltransferase (TPMT) results in severe and life-threatening hematopoietic toxicity if patients receive standard doses of mercaptopurine and azathioprine. Gene duplication of cytochrome P4502D6 (CYP2D6), which metabolizes many antidepressants, has been identified as a mechanism of poor response in the treatment of depression. There is also a growing list of genetic polymorphisms in drug targets that have been shown to influence drug response. A major limitation that has heretofore moderated the use of pharmacogenetic testing in the clinical setting is the lack of prospective clinical trials demonstrating that such testing can improve the benefit/risk ratio of drug therapy. |
| Формат | application.pdf |
| Издатель | Annual Reviews |
| Копирайт | Annual Reviews |
| Название | Pharmacogenomics and Individualized Drug Therapy |
| DOI | 10.1146/annurev.med.56.082103.104724 |
| Print ISSN | 0066-4219 |
| Журнал | Annual Review of Medicine |
| Том | 57 |
| Первая страница | 119 |
| Последняя страница | 137 |
| Аффилиация | Eichelbaum, Michel; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstr. 112, D-70376 Stuttgart, Germany; email: michel.eichelbaum@ikp-stuttgart.de |
